Sputnik V vaccine trials of phase 1 and 2 have been successfully completed in Russia and approved by regulators by the Russian health ministry for public use in Russia. According to the preliminary findings report published in Lancet Journal, non-randomised vaccine trials on 76 people show that two formulations of the vaccine have a good safety profile detected over a span of 42 days, and induce antibody responses in all participants within 21 days. Earlier phase trials of Sputnik V were positive and induced antibodies in all participants. According to researchers, secondary results also suggest that the vaccine produces a T cell response within 28 days.
Russia, on 7th September, 2020, said that it will now begin clinical trials of Sputnik V in India. Russia is also planning to conduct its clinical trials in various countries including the UAE and Philippines. Preliminary results of the phase 3 trials will be published by October- November 2020. According to a report published on the official website of Sputnik V, at least 20 countries have showcased their interest in Sputnik V, and India is one them. India is looking forward to a partnership with Russia to produce the COVID-19 vaccine.
Reports of phase 1 and 2 trials of Sputnik V have been submitted to India. Researchers are now analysing the vaccine report properly. The Sputnik V vaccine so far consists of two shots that use different versions of adenoviruses.
The World Health Organisation has stated that it would never endorse a vaccine that has not been proven safe and effective. However, countries are in a rush to produce a vaccine against the coronavirus, though experts are scared that this might lead to use of a shortcut to prepare the vaccine. This might also put a risk on people’s lives